Amylyx Pharmaceuticals, Inc. (AMLX) stock
AMLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$26.62−0.90 (-3.27%)
Close on Nov 18, 2026Market cap $2.97BP/E –Yield –
Amylyx Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Amylyx Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$162.10M. For fiscal 2025 it was -$153.29M. The highest annual figure on record is $38.80M in fiscal 2023.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$153.29M | – |
| FY2024 | Dec 31, 2024 | -$314.73M | -911.1% |
| FY2023 | Dec 31, 2023 | $38.80M | – |
| FY2022 | Dec 31, 2022 | -$201.34M | – |
| FY2021 | Dec 31, 2021 | -$82.69M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$45.69M | – |
| Q1 FY2026 | Mar 31, 2026 | -$43.78M | – |
| Q4 FY2025 | Dec 31, 2025 | -$36.61M | – |
| Q3 FY2025 | Sep 30, 2025 | -$36.03M | – |
| Q2 FY2025 | Jun 30, 2025 | -$42.86M | – |
| Q1 FY2025 | Mar 31, 2025 | -$37.80M | – |
| Q4 FY2024 | Dec 31, 2024 | -$40.65M | -2202.1% |
| Q3 FY2024 | Sep 30, 2024 | -$75.66M | -504.2% |
| Q2 FY2024 | Jun 30, 2024 | -$76.29M | -477.6% |
| Q1 FY2024 | Mar 31, 2024 | -$122.13M | – |
| Q4 FY2023 | Dec 31, 2023 | $1.93M | – |
| Q3 FY2023 | Sep 30, 2023 | $18.72M | – |
| Q2 FY2023 | Jun 30, 2023 | $20.20M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.05M | – |
| Q4 FY2022 | Dec 31, 2022 | -$44.59M | – |
| Q3 FY2022 | Sep 30, 2022 | -$54.68M | – |
| Q2 FY2022 | Jun 30, 2022 | -$54.25M | – |
| Q1 FY2022 | Mar 31, 2022 | -$47.81M | – |
| Q4 FY2021 | Dec 31, 2021 | -$28.32M | – |
| Q3 FY2021 | Sep 30, 2021 | -$22.92M | – |
| Q2 FY2021 | Jun 30, 2021 | -$18.59M | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.87M | – |
See a number that looks wrong?